Investor Relations

Corporate Profile

Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.

Press Releases

Aug 30, 2018
Autolus to Present at Upcoming Investor Conferences
LONDON , Aug. 30, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will be participating in the following, upcoming investor conferences: Dr.


Nov 14 - Nov 15, 2018

Jefferies 2018 London Healthcare Conference

Dec 1 - Dec 4, 2018

American Society of Hematology (ASH)